Capricor Therapeutics, Inc. CAPR

CAPR Company Overview

Capricor Therapeutics, Inc. is a U.S.-based biotechnology company focused on the development of cell and exosome-based therapeutics for rare diseases, with a primary emphasis on muscular and inflammatory disorders. The company operates within the biotechnology and regenerative medicine industries and is best known for advancing therapies targeting Duchenne muscular dystrophy (DMD) and related cardiomyopathies. Its lead product candidate, deramiocel, is an allogeneic cardiac-derived cell therapy designed to address the cardiac complications associated with DMD, while its exosome platform is being explored for therapeutic and vaccine-related applications.

The company’s core revenue drivers have historically consisted of research collaborations, grant funding, licensing arrangements, and milestone-based payments rather than large-scale commercial product sales, as its pipeline remains primarily in clinical development. Capricor evolved from earlier regenerative medicine initiatives centered on cardiac cell therapy and shifted strategic focus toward rare disease applications after observing potential benefits in DMD-related cardiac dysfunction. The company has positioned itself within a specialized niche of regenerative therapeutics by leveraging proprietary cell manufacturing and exosome technologies targeting unmet medical needs in rare pediatric diseases.